Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details) - USD ($) $ in Millions		1 Months Ended	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 31, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Revenue milestones			$ 2,857.2	$ 5,138.5	$ 5,822.3	$ 7,667.2
Subsequent Event
Disaggregation of Revenue [Line Items]
Up-front payment to collaborating party		$ 900.0
Sanofi Collaboration Agreement, Immuno-oncology | Subsequent Event
Disaggregation of Revenue [Line Items]
Royalty payment to collaborating party, percentage of net product sales		11.00%
Sanofi Collaboration Agreement, Immuno-oncology | Regulatory Milestone | Sanofi | Subsequent Event
Disaggregation of Revenue [Line Items]
Revenue milestones		$ 100.0
Sanofi Collaboration Agreement, Immuno-oncology | Sales-Based Milestones | Sanofi | Subsequent Event
Disaggregation of Revenue [Line Items]
Revenue milestones		$ 100.0
Sanofi Collaboration Agreement, Amended and Restated Immuno-oncology License and Collaboration Agreement | Subsequent Event
Disaggregation of Revenue [Line Items]
Royalty payment to collaborating party, percentage of net product sales	0.50%
Remaining performance obligation	$ 35.0